The paper that reports the first use of click chemistry inside patients. A doxorubicin prodrug switched on at an injected tumour was given at up to 15 times the usual doxorubicin dose without the dose-limiting side effects the trial was watching for.
Written by Shasqi scientists with clinical co-authors including the trial's principal investigator, this paper follows SQ3370 from mouse and dog studies into the dose-escalation part of its first trial in people (NCT04106492). SQ3370 is a clickable agent placed at the tumour that reacts with a chemically attenuated doxorubicin and releases the active drug in place.
In mice it slowed tumour growth across several models, releasing doxorubicin in tumours at concentrations the authors say conventional treatment cannot reach. It was given safely at 8.9 times the veterinary doxorubicin dose in dogs and 15 times the conventional dose in patients, with no protocol-defined dose-limiting toxicity. In patients it changed the pharmacokinetics of active doxorubicin and was followed by T-cell-dependent immune responses, including expansion and activation of cytotoxic CD8 T cells in tumours and in the blood.
The abstract reports safety, drug levels and immune changes. It gives no response rate; the efficacy results of the same trial are in a separate preprint.
It establishes that a click reaction between two separately given substances can be run inside a person, and that capping doxorubicin this way lets far more of it be given. It does not establish that patients do better: the abstract reports no tumour responses, and the trial's phase 2a part later found a response rate comparable to standard doxorubicin.
Shares Sant P. Chawla, SQ3370 in advanced solid tumours and soft tissue sarcoma (SQ3370-001, phase 1/2a), SQ3370, Shasqi.
Shares SQ3370, Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares SQ3370, Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares SQ3370, Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Shasqi, Click-activated prodrugs (bioorthogonal drug activation in the body).
Shares Sant P. Chawla, SQ3370 in advanced solid tumours and soft tissue sarcoma (SQ3370-001, phase 1/2a), Sarcomas (soft tissue, bone, GIST).
Shares SQ3370 in advanced solid tumours and soft tissue sarcoma (SQ3370-001, phase 1/2a), SQ3370.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/